United Therapeutics Corporation

NasdaqGS:UTHR Voorraadrapport

Marktkapitalisatie: US$16.6b

United Therapeutics Dividenden en inkoop

Dividend criteriumcontroles 0/6

United Therapeutics heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

5.2%

Terugkoop Rendement

Totaal aandeelhoudersrendement5.2%
Toekomstig dividendrendement0%
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente updates van dividend en inkoop

Recent updates

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 14

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

United Therapeutics: Economics Support Compounding Ability

Aug 20

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jul 26
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Jul 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van UTHR in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van UTHR zijn gestegen.


Dividendrendement versus markt

United Therapeutics Dividendrendement versus markt
Hoe verhoudt UTHR dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (UTHR)n/a
Markt onderkant 25% (US)1.4%
Markt Top 25% (US)4.2%
Gemiddelde industrie (Biotechs)2.3%
Analist prognose (UTHR) (tot 3 jaar)0%

Opmerkelijk dividend: Het dividendrendement van UTHR kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van UTHR kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.


Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio UTHR te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat UTHR geen uitbetalingen heeft gerapporteerd.


Ontdek bedrijven met een sterk dividend